BioSpace News Archive

Maxwell Biosciences (“Maxwell”), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced data on its CLAROMER drug discovery platform’s treatment and prevention of SARS-CoV-2, and potentially other respiratory viruses, through a series of pre-clinical in vitro and in vivo studies.

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that the company has produced 1.5 mg psilocybin microdose capsules

The latest market analysis report published by Reports and Data, titled ‘Global Bradykinesia Treatment Market – Forecast to 2030,’ thoroughly examines the Bradykinesia Treatment industry to provide essential data & information for the targeted readers.

Haleon plc announced the commencement of offers to exchange seven series of outstanding unregistered notes issued by GSK Consumer Healthcare Capital US LLC and GSK Consumer Healthcare Capital UK plc, as previously disclosed in Haleon’s public filings and pursuant to a registration rights agreement entered into at the time of the original issuance of the notes.

MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to improving survival outcomes for patients with cancer, today announced its half year financial results for the six-month period ended June 30, 2022 and provided a business overview.

Backed by innovative new technology and industry-leading subject matter experts, SPARC Academy delivers on-demand, asynchronous EHR training

Latest Study on “Epilepsy Therapeutics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced today that the company’s lead product, TC-002 (latanoprost ophthalmic solution 0.005%) met the primary and all secondary endpoints in the CLEAR Phase 3 pivotal trial.

Illumina, Inc. announced the launch of the NovaSeq™ X Series, new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing.

According to latest report study, the global Red Biotechnology market reached value at USD 357.9 Billion in 2021 and projected to hit over USD 609.8 billion by 2030.